In this cross-sectional study we compared the abilities of lipoprotein(a) [Lp(a)], plasminogen activator inhibitor-1 (PAI- 1), and tissue plasminogen activator (TPA) to discriminate between individuals with and without a history of stroke from among subjects in a metabolic ward. A total of 210 subjects (108 men and 102 women: mean age, 63.8 years; range, 31 to 86 years) provided plasma and DNA samples for the study. Of these, 51 men and 50 women had a history of ischemia stroke. The 109 subjects without a history of stroke were compared with those with such a history for major risk factors for ischemic events. Mean plasma TPA and PAI- 1 levels significantly (P50 mg/dL were more common among stroke patients (8 with versus 1 without, P2 test). A molecular variation in the 5' flanking region of the apo(a) gene that has been related to elevated Lp(a) plasma levels (G/A-914) was not strongly correlated with circulating levels of Lp(a), nor did Lp(a) levels correlate with a polymorphism of the apo(a) gene (G/A-21), which is strongly linked (P50 mg/dL) plasma levels of the lipoprotein.
|Number of pages||9|
|Journal||Arteriosclerosis, Thrombosis, and Vascular Biology|
|Publication status||Published - 1996|
- fibrinolytic variables
- ischemic stroke
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine